{"id":"myfortic-escalation","safety":{"commonSideEffects":[{"rate":"19-25%","effect":"Diarrhea"},{"rate":"12-15%","effect":"Nausea"},{"rate":"10-12%","effect":"Vomiting"},{"rate":"8-12%","effect":"Abdominal pain"},{"rate":"20-30%","effect":"Infection"},{"rate":"15-20%","effect":"Leukopenia"},{"rate":"10-15%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Myfortic selectively inhibits IMPDH type II, an enzyme critical for guanosine nucleotide synthesis in lymphocytes. By depleting guanosine nucleotides, it preferentially suppresses proliferation of T and B cells while sparing other cell types, thereby reducing the immune response against transplanted organs. The escalation formulation refers to dose titration protocols used in transplant maintenance therapy.","oneSentence":"Myfortic (mycophenolate sodium) is an inosine monophosphate dehydrogenase (IMPDH) inhibitor that suppresses T and B lymphocyte proliferation to prevent organ rejection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:47.671Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute organ rejection in adult patients receiving allogeneic renal transplants (as part of combination immunosuppressive regimen)"}]},"trialDetails":[{"nctId":"NCT02579967","phase":"PHASE2","title":"Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-19","conditions":"Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency, Immune System Diseases","enrollment":354},{"nctId":"NCT05436418","phase":"PHASE1, PHASE2","title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-18","conditions":"Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation","enrollment":260},{"nctId":"NCT06365437","phase":"PHASE2","title":"A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation","status":"TERMINATED","sponsor":"ITB-Med LLC","startDate":"2021-06-06","conditions":"Kidney Transplantation","enrollment":33},{"nctId":"NCT05327023","phase":"PHASE1, PHASE2","title":"Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-05-23","conditions":"Hematologic Neoplasms","enrollment":430},{"nctId":"NCT04180059","phase":"PHASE1","title":"Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2020-02-09","conditions":"Haematologic Disease","enrollment":6},{"nctId":"NCT07162038","phase":"PHASE1","title":"Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-11-14","conditions":"Hematologic Malignancies, Hematologic Neoplasms","enrollment":155},{"nctId":"NCT06653023","phase":"EARLY_PHASE1","title":"Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer","status":"RECRUITING","sponsor":"Wondercel Biotech (ShenZhen)","startDate":"2024-10-23","conditions":"HCC - Hepatocellular Carcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":60},{"nctId":"NCT05236036","phase":"PHASE1","title":"Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2022-08-08","conditions":"Astrocytoma, Glioblastoma, Glioblastoma, IDH-Wildtype","enrollment":60},{"nctId":"NCT03983850","phase":"PHASE1, PHASE2","title":"Optimizing PTCy Dose and Timing","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-09","conditions":"Graft Versus Host Disease, Hematologic Neoplasms","enrollment":105},{"nctId":"NCT07080125","phase":"","title":"A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-06-17","conditions":"Interstitial Lung Diseases, Systemic Sclerosis Associated Interstitial Lung Disease","enrollment":2000},{"nctId":"NCT01810588","phase":"PHASE2","title":"Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2012-10-16","conditions":"Hematologic Malignancies","enrollment":270},{"nctId":"NCT07108530","phase":"PHASE2","title":"Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-06","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT04477200","phase":"PHASE1","title":"Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-08-05","conditions":"Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV","enrollment":68},{"nctId":"NCT03478215","phase":"PHASE2","title":"Mesenchymal Stromal Cells in Living Donor Kidney Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2016-12","conditions":"Renal Transplantation, Mesenchymal Stem Cells","enrollment":24},{"nctId":"NCT04311632","phase":"PHASE2","title":"A Dose Escalation Study in de Novo Renal Transplantation","status":"COMPLETED","sponsor":"ITB-Med LLC","startDate":"2021-05-26","conditions":"Kidney Transplantation","enrollment":13},{"nctId":"NCT06394232","phase":"PHASE1, PHASE2","title":"Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.","status":"RECRUITING","sponsor":"Eyestem Research Pvt. Ltd.","startDate":"2024-06-04","conditions":"Retinal Disease, Macular Degeneration, Age-Related Macular Degeneration","enrollment":54},{"nctId":"NCT00423514","phase":"PHASE1, PHASE2","title":"Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-11-20","conditions":"Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes","enrollment":38},{"nctId":"NCT00352976","phase":"PHASE2, PHASE3","title":"TBI Dose De-escalation for Fanconi Anemia","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2006-05-18","conditions":"Fanconi Anemia","enrollment":83},{"nctId":"NCT01020539","phase":"PHASE1","title":"Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia","status":"COMPLETED","sponsor":"Columbia University","startDate":"2002-09-11","conditions":"Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Juvenile Myelomonocytic Leukemia","enrollment":18},{"nctId":"NCT00397813","phase":"PHASE2","title":"Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2006-01","conditions":"Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome","enrollment":77},{"nctId":"NCT00040846","phase":"PHASE2","title":"Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2001-11","conditions":"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","enrollment":60},{"nctId":"NCT00453388","phase":"PHASE2","title":"Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2007-02","conditions":"Acute Myeloid Leukemia in Remission, de Novo Myelodysplastic Syndrome, Fanconi Anemia","enrollment":6},{"nctId":"NCT01379209","phase":"PHASE1, PHASE2","title":"Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)","status":"COMPLETED","sponsor":"Regimmune Corporation","startDate":"2011-09","conditions":"Graft Versus Host Disease","enrollment":68},{"nctId":"NCT01634217","phase":"PHASE1","title":"Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2013-11-08","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia","enrollment":16},{"nctId":"NCT01093885","phase":"NA","title":"Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2010-02","conditions":"Systemic Sclerosis, Scleroderma","enrollment":15},{"nctId":"NCT02649504","phase":"PHASE3","title":"Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2016-12-01","conditions":"Immune Thrombocytopenia","enrollment":""},{"nctId":"NCT00376519","phase":"PHASE1","title":"Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2007-05","conditions":"Graft Versus Host Disease, Leukemia, Lymphoma","enrollment":3},{"nctId":"NCT00118352","phase":"PHASE2","title":"Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2005-03","conditions":"Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission","enrollment":12},{"nctId":"NCT00669890","phase":"PHASE1","title":"Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML","status":"TERMINATED","sponsor":"New York Medical College","startDate":"2004-05","conditions":"Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome","enrollment":12},{"nctId":"NCT01044303","phase":"PHASE4","title":"Reducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients (DSA Study)","status":"COMPLETED","sponsor":"East Carolina University","startDate":"2010-01","conditions":"Transplant; Failure, Kidney","enrollment":32},{"nctId":"NCT00997958","phase":"PHASE1","title":"Study of CellCept for Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Columbia University","startDate":"2004-06","conditions":"Pancreatic Cancer","enrollment":12},{"nctId":"NCT00810602","phase":"PHASE1, PHASE2","title":"Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Pavan Reddy, MD","startDate":"2009-01","conditions":"Hematologic Malignancies, Graft vs Host Disease","enrollment":61},{"nctId":"NCT00119340","phase":"PHASE1, PHASE2","title":"Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2005-04","conditions":"Leukemia","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Enteric-coated mycophenolate sodium"],"phase":"marketed","status":"active","brandName":"Myfortic Escalation","genericName":"Myfortic Escalation","companyName":"East Carolina University","companyId":"east-carolina-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Myfortic (mycophenolate sodium) is an inosine monophosphate dehydrogenase (IMPDH) inhibitor that suppresses T and B lymphocyte proliferation to prevent organ rejection. Used for Prevention of acute organ rejection in adult patients receiving allogeneic renal transplants (as part of combination immunosuppressive regimen).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}